Marie Terroir1, Isabelle Borget2, François Bidault3, Marcel Ricard4, Frédéric Deschamps5, Dana Hartl6, Lambros Tselikas5, Laurent Dercle7, Jean Lumbroso7, Eric Baudin7, Amandine Berdelou7, Désirée Deandreis7, Martin Schlumberger7, Sophie Leboulleux7. 1. Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and Université Paris Saclay, 114 Rue Edouard Vaillant, 94805, Villejuif, France. marie.terroir-cassou-mounat@gustaveroussy.fr. 2. Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris Sud, 114 Rue Edouard Vaillant, 94805, Villejuif, France. 3. Department of Radiology, Gustave Roussy, 114 Rue Edouard Vaillant, 94805, Villejuif, France. 4. Department of Physic, Gustave Roussy, 114 Rue Edouard Vaillant, 94805, Villejuif, France. 5. Department of Interventional Radiology, 114 Rue Edouard Vaillant, 94805, Villejuif, France. 6. Department of Surgery, Gustave Roussy, 114 Rue Edouard Vaillant, 94805, Villejuif, France. 7. Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and Université Paris Saclay, 114 Rue Edouard Vaillant, 94805, Villejuif, France.
Abstract
PURPOSE: In patients with metastatic differentiated thyroid carcinoma (DTC), fluorodeoxyglucose (FDG) uptake as well as age, tumor size and radioactive iodine (RAI) uptake are prognostic factors for survival. High FDG uptake is a poor prognostic factor and lesions with high FDG uptake are often considered aggressive, but the predictive value of FDG uptake for morphological progression is unknown. The principal aim of this retrospective single center study was to determine whether the intensity of FDG uptake was correlated on a per lesion analysis with tumor growth rate (TGR) expressed as the percentage of increase in tumor size during 1 year (1-year TGR). METHODS: Fifty five patients with DTC were included between July 2012 and May 2014 with the following criteria: (i) at least one distant metastasis measuring ≥ 1 cm in diameter on CT scan (ii) evaluation by FDG-positron emission tomography/computed tomography (PET/CT) performed at our center (iii) at least one CT or another FDG-PET/CT performed 3 to 12 months after the reference FDG-PET/CT in the absence of systemic or local treatment between the two imaging procedures. RESULTS: One hundred and fifty-six metastatic lesions located in lungs (63), neck lymph nodes (28), chest lymph nodes (42), bone (11), liver (2) and other sites (12) were studied. The median size was 16 mm, median SUVmax/lesion: 8.7; median metabolic tumor volume/lesion (Metab.TV/lesion): 3.7 cm3. The median 1-year TGR was 40.68 %. SUVmax and Metab.TV/lesion were not correlated to their 1-year TGR (p = 0.38 and p = 0.74 respectively). Among single patients with multiple lesions, the lesions with the highest SUVmax/lesion or the highest Metab.TV/lesion did not disclose the higher 1-year TGR. CONCLUSION: The intensity of FDG uptake on a per lesion analysis is not correlated to its 1-year TGR and cannot be used as a surrogate marker of tumour progression.
PURPOSE: In patients with metastatic differentiated thyroid carcinoma (DTC), fluorodeoxyglucose (FDG) uptake as well as age, tumor size and radioactive iodine (RAI) uptake are prognostic factors for survival. High FDG uptake is a poor prognostic factor and lesions with high FDG uptake are often considered aggressive, but the predictive value of FDG uptake for morphological progression is unknown. The principal aim of this retrospective single center study was to determine whether the intensity of FDG uptake was correlated on a per lesion analysis with tumor growth rate (TGR) expressed as the percentage of increase in tumor size during 1 year (1-year TGR). METHODS: Fifty five patients with DTC were included between July 2012 and May 2014 with the following criteria: (i) at least one distant metastasis measuring ≥ 1 cm in diameter on CT scan (ii) evaluation by FDG-positron emission tomography/computed tomography (PET/CT) performed at our center (iii) at least one CT or another FDG-PET/CT performed 3 to 12 months after the reference FDG-PET/CT in the absence of systemic or local treatment between the two imaging procedures. RESULTS: One hundred and fifty-six metastatic lesions located in lungs (63), neck lymph nodes (28), chest lymph nodes (42), bone (11), liver (2) and other sites (12) were studied. The median size was 16 mm, median SUVmax/lesion: 8.7; median metabolic tumor volume/lesion (Metab.TV/lesion): 3.7 cm3. The median 1-year TGR was 40.68 %. SUVmax and Metab.TV/lesion were not correlated to their 1-year TGR (p = 0.38 and p = 0.74 respectively). Among single patients with multiple lesions, the lesions with the highest SUVmax/lesion or the highest Metab.TV/lesion did not disclose the higher 1-year TGR. CONCLUSION: The intensity of FDG uptake on a per lesion analysis is not correlated to its 1-year TGR and cannot be used as a surrogate marker of tumour progression.
Authors: C Durante; N Haddy; E Baudin; S Leboulleux; D Hartl; J P Travagli; B Caillou; M Ricard; J D Lumbroso; F De Vathaire; M Schlumberger Journal: J Clin Endocrinol Metab Date: 2006-05-09 Impact factor: 5.958
Authors: Carlos Gomez-Roca; Serge Koscielny; Vincent Ribrag; Clarisse Dromain; Inès Marzouk; François Bidault; Ratislav Bahleda; Charles Ferté; Christophe Massard; Jean-Charles Soria Journal: Eur J Cancer Date: 2011-07-15 Impact factor: 9.162
Authors: R L Cazzato; F Bonichon; X Buy; Y Godbert; B H de Figuereido; V Pointillart; J Palussière Journal: Eur J Surg Oncol Date: 2015-06-21 Impact factor: 4.424
Authors: W Wang; S M Larson; M Fazzari; S K Tickoo; K Kolbert; G Sgouros; H Yeung; H Macapinlac; J Rosai; R J Robbins Journal: J Clin Endocrinol Metab Date: 2000-03 Impact factor: 5.958
Authors: Heather A Jacene; Sophie Leboulleux; Shingo Baba; Daniel Chatzifotiadis; Behnaz Goudarzi; Oleg Teytelbaum; Karen M Horton; Ihab Kamel; Katarzyna J Macura; Hua-Ling Tsai; Jeanne Kowalski; Richard L Wahl Journal: J Nucl Med Date: 2009-10-16 Impact factor: 10.057
Authors: T de Baère; A Aupérin; F Deschamps; P Chevallier; Y Gaubert; V Boige; M Fonck; B Escudier; J Palussiére Journal: Ann Oncol Date: 2015-02-16 Impact factor: 32.976
Authors: Matthias Dittmann; José Manuel Gonzalez Carvalho; Kambiz Rahbar; Michael Schäfers; Michael Claesener; Burkhard Riemann; Robert Seifert Journal: Eur J Nucl Med Mol Imaging Date: 2020-04-04 Impact factor: 9.236